Molecular Formula | C22H23F3N4O4 |
Molar Mass | 464.44 |
Density | 1.41±0.1 g/cm3(Predicted) |
Boling Point | 818.7±65.0 °C(Predicted) |
Solubility | DMSO: ≥ 34 mg/mL |
pKa | 12.75±0.20(Predicted) |
Storage Condition | -20℃ |
In vitro study | LY3039478 is a potent inhibitor of the cleavage of the intracellular region of Notch-1, with an IC50 of approximately 1 nM in most of the tumor cells examined. LY3039478 also potently inhibits mutant Notch receptor activity. LY3039478 significantly inhibited the growth of two renal clear cell carcinoma cells. Its treatment can reduce the expression of Myc and cyclin A1, causing cell arrest in G0/G1 phase of clear cell carcinoma cells. |
In vivo study | In rats, its oral bioavailability was 65%,CL = 98 mL/min/kg, VDss = 4.9 L/kg. In dogs, the oral bioavailability was 67%,CL = 3.8 mL/min/kg, VDss = 1.4 L/kg. In xenograft tumor models, LY3039478 can inhibit the cleavage of N1ICD and the expression of Notch target genes in the tumor microenvironment. In a xenograft model that relies on Notch signaling, inhibition of Notch clipping induces apoptosis. In immunodeficient NSG-bearing mice (transplanted with 769-P CCRCC cells), LY3039478 significantly improved survival and delayed tumor growth. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.153 ml | 10.766 ml | 21.531 ml |
5 mM | 0.431 ml | 2.153 ml | 4.306 ml |
10 mM | 0.215 ml | 1.077 ml | 2.153 ml |
5 mM | 0.043 ml | 0.215 ml | 0.431 ml |